Gautam J, Banskota S, Lee H, Lee Y, Jeon Y, Kim J
Exp Mol Med. 2018; 50(9):1-14.
PMID: 30185799
PMC: 6123788.
DOI: 10.1038/s12276-018-0135-9.
Kulahci O, Esen H, Asut E, Gungor S
J Breast Health. 2017; 13(1):5-9.
PMID: 28331761
PMC: 5351466.
DOI: 10.5152/tjbh.2016.3142.
Kapoor S, Kaur G, Sikka P
Dent Res J (Isfahan). 2014; 11(2):204-11.
PMID: 24932191
PMC: 4052646.
Ruhoy S, Clarke M
Endocr Pathol. 1997; 8(1):49-57.
PMID: 12114671
DOI: 10.1007/BF02739707.
Khanna , Tokuda , Shibuya , Tanaka , Sekine , Tajima
Breast Cancer. 1995; 2(1):51-58.
PMID: 11091532
DOI: 10.1007/BF02966896.
Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Jahkola T, Toivonen T, von Smitten K, Virtanen I, Wasenius V, Blomqvist C
Br J Cancer. 1999; 80(1-2):167-74.
PMID: 10389993
PMC: 2363020.
DOI: 10.1038/sj.bjc.6690336.
Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer.
Falcon O, Chirino R, Leon L, Torres S, Fernandez L, Garcia-Hernandez J
Br J Cancer. 1999; 79(3-4):570-6.
PMID: 10027332
PMC: 2362431.
DOI: 10.1038/sj.bjc.6690090.
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
Foekens J, Look M, Bolt-de Vries J, Meijer-van Gelder M, van Putten W, Klijn J
Br J Cancer. 1999; 79(2):300-7.
PMID: 9888472
PMC: 2362199.
DOI: 10.1038/sj.bjc.6690048.
Prognostic value of cathepsin D expression and association with histomorphological subtypes in breast cancer.
Losch A, Tempfer C, Kohlberger P, Joura E, Denk M, ZAJIC B
Br J Cancer. 1998; 78(2):205-9.
PMID: 9683294
PMC: 2062888.
DOI: 10.1038/bjc.1998.465.
Cathepsin D immunoreactivity in ovarian cancer: correlation with prognostic factors.
Athanassiadou P, Sakellariou V, Petrakakou E, Athanassiades P, Zerva C, Liossi A
Pathol Oncol Res. 1998; 4(2):103-7.
PMID: 9654594
DOI: 10.1007/BF02904702.
Cathepsin D detected by automated and quantitative immunohistochemistry in breast carcinomas: correlation with overall and disease free survival.
Charpin C, Garcia S, Bouvier C, Martini F, Lavaut M, Allasia C
J Clin Pathol. 1997; 50(7):586-90.
PMID: 9306940
PMC: 500062.
DOI: 10.1136/jcp.50.7.586.
Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis.
Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S, Messori A
Br J Cancer. 1997; 76(5):661-6.
PMID: 9303368
PMC: 2228021.
DOI: 10.1038/bjc.1997.442.
Prospective evaluation of prognostic factors in operable breast cancer.
Hawkins R, Tesdale A, Killen M, Jack W, Chetty U, Dixon J
Br J Cancer. 1996; 74(9):1469-78.
PMID: 8912547
PMC: 2074769.
DOI: 10.1038/bjc.1996.567.
Current and future strategies to block tumor angiogenesis, invasion, and metastasis.
Effert P, Gastl G, Strohmeyer T
World J Urol. 1996; 14(3):131-40.
PMID: 8806191
DOI: 10.1007/BF00186892.
Expression of L-PHA-binding proteins in breast cancer: reconstitution and molecular characterization of beta 1-6 branched oligosaccharides in three-dimensional cell culture.
Taeda Y, Nose M, Hiraizumi S, Ohuchi N
Breast Cancer Res Treat. 1996; 38(3):313-24.
PMID: 8739085
DOI: 10.1007/BF01806151.
Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods.
Gohring U, Scharl A, Thelen U, Ahr A, Crombach G, Titius B
J Clin Pathol. 1996; 49(1):57-64.
PMID: 8666688
PMC: 1023159.
DOI: 10.1136/jcp.49.1.57.
Lysosomal protease cathepsin D is a prognostic marker in endometrial cancer.
Losch A, Kohlberger P, Gitsch G, Kaider A, Breitenecker G, Kainz C
Br J Cancer. 1996; 73(12):1525-8.
PMID: 8664123
PMC: 2074555.
DOI: 10.1038/bjc.1996.287.
Immunohistochemical expression of the mucin-type glycoprotein A-80 and prognosis in human breast cancer.
Eriksson E, Schimmelpenning H, Rutqvist L, Johansson H, Auer G
Br J Cancer. 1993; 67(6):1418-22.
PMID: 8512827
PMC: 1968526.
DOI: 10.1038/bjc.1993.263.
Cathepsin D in breast secretions from women with breast cancer.
Sanchez L, Ferrando A, Diez-Itza I, Vizoso F, Ruibal A, Lopez-Otin C
Br J Cancer. 1993; 67(5):1076-81.
PMID: 8494701
PMC: 1968431.
DOI: 10.1038/bjc.1993.197.
Prognostic significance of cathepsin-D in patients with breast cancer.
Winstanley J, Leinster S, Cooke T, Westley B, Rudland P
Br J Cancer. 1993; 67(4):767-72.
PMID: 8471433
PMC: 1968341.
DOI: 10.1038/bjc.1993.139.